CL2018003444A1 - Derivados de adenosina para uso en el tratamiento del cancer. - Google Patents

Derivados de adenosina para uso en el tratamiento del cancer.

Info

Publication number
CL2018003444A1
CL2018003444A1 CL2018003444A CL2018003444A CL2018003444A1 CL 2018003444 A1 CL2018003444 A1 CL 2018003444A1 CL 2018003444 A CL2018003444 A CL 2018003444A CL 2018003444 A CL2018003444 A CL 2018003444A CL 2018003444 A1 CL2018003444 A1 CL 2018003444A1
Authority
CL
Chile
Prior art keywords
cancer
treatment
adenosine derivatives
adenosine
derivatives
Prior art date
Application number
CL2018003444A
Other languages
English (en)
Inventor
Hugh Griffith
Michaela Serpi
Magdalena Slusarczyc
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of CL2018003444A1 publication Critical patent/CL2018003444A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
CL2018003444A 2016-06-01 2018-11-30 Derivados de adenosina para uso en el tratamiento del cancer. CL2018003444A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1609602.6A GB201609602D0 (en) 2016-06-01 2016-06-01 Chemical compounds

Publications (1)

Publication Number Publication Date
CL2018003444A1 true CL2018003444A1 (es) 2019-05-10

Family

ID=56410851

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003444A CL2018003444A1 (es) 2016-06-01 2018-11-30 Derivados de adenosina para uso en el tratamiento del cancer.

Country Status (17)

Country Link
US (1) US20190375778A1 (es)
EP (1) EP3464308B1 (es)
JP (1) JP2019520345A (es)
KR (1) KR20190015355A (es)
CN (1) CN109563122A (es)
AU (1) AU2017273120A1 (es)
BR (1) BR112018074972A2 (es)
CA (1) CA3025435A1 (es)
CL (1) CL2018003444A1 (es)
EA (1) EA201892802A1 (es)
GB (1) GB201609602D0 (es)
IL (1) IL263120A (es)
MX (1) MX2018014849A (es)
PH (1) PH12018502497A1 (es)
SG (1) SG11201810146SA (es)
WO (1) WO2017207989A1 (es)
ZA (1) ZA201807810B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
DK3224268T3 (da) 2014-11-28 2019-09-02 NuCana plc Nye 2'- og/eller 5'-aminosyreesterphosphoramidat 3'-deoxyadenosinderivater som anti-cancerforbindelser
KR102424709B1 (ko) 2016-05-31 2022-07-22 칼비스타 파마슈티컬즈 리미티드 혈장 칼리크레인 저해제로서 피라졸 유도체
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
HUE057912T2 (hu) 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
GB201820685D0 (en) 2018-12-19 2019-01-30 NuCana plc Synthesis of 8-chloroadenosine derivatives
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
SI3235824T1 (sl) * 2012-11-16 2019-08-30 University College Cardiff Consultants Limited Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
CN103435672A (zh) * 2013-04-25 2013-12-11 刘沛 含有取代苄基的新型核苷磷酸酯前药的结构与合成
US10030044B2 (en) * 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer

Also Published As

Publication number Publication date
EA201892802A1 (ru) 2019-06-28
GB201609602D0 (en) 2016-07-13
ZA201807810B (en) 2021-04-28
WO2017207989A1 (en) 2017-12-07
PH12018502497A1 (en) 2019-04-08
US20190375778A1 (en) 2019-12-12
KR20190015355A (ko) 2019-02-13
MX2018014849A (es) 2019-03-14
SG11201810146SA (en) 2018-12-28
JP2019520345A (ja) 2019-07-18
IL263120A (en) 2018-12-31
CN109563122A (zh) 2019-04-02
EP3464308A1 (en) 2019-04-10
EP3464308B1 (en) 2020-08-19
BR112018074972A2 (pt) 2019-03-12
CA3025435A1 (en) 2017-12-07
AU2017273120A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
SV2018005610A (es) Derivados de oxopiridina sustituidos
HK1256283A1 (zh) 治療癌症有用的二氫咪唑並吡嗪酮衍生物
ES2764110T8 (es) Conjugado anticuerpo-fármaco y su utilización para el tratamiento del cáncer
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2014002358A1 (es) Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona; metodos de preparacion; composiciones farmaceuticas que las comprenden y uso en el tratamiento del cancer.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
CL2018003443A1 (es) Tratamientos para el cancer.
IL276733A (en) Use of Aribolin in cancer treatment
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112016027043A2 (pt) Combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
ES2727103T8 (es) Conjugado anticuerpo-fármaco para IGF-1R y su utilización para el tratamiento del cáncer
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
ES2968042T3 (es) Uso de DREADD para la modulación neuronal en el tratamiento de enfermedades neuronales
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
DK3383872T3 (da) 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling
CU20150176A7 (es) Derivados de prodroga de triazolpiridinas sustituídas
DK3217980T3 (da) Ciclopirox, ciclopirox-olamin, eller et ciclopirox-prodrug til anvendelse i behandlingen af blærekræft
BR112017001384A2 (pt) composto para uso em tratamento anti-helmíntico
IL253933A0 (en) History of pyrimidine use in the treatment of cancer
ES2759940T8 (es) Compuestos de 1,3,4-tiadiazol y su uso para tratar el cáncer
DK3407909T3 (da) Cancerbehandling
BR112016021231A2 (pt) derivados de hexose, preparação e uso destes.
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도